As CYP2E1 overexpression inhibited migration of highly invasive MDA-MB-231 breast cancer cells expressing mutant p53, the authors concluded that manipulation of CYP2E1 protein expression could be potentially exploited in breast cancer therapy (Leung et al. 2013). This evidence concerns the gene TP53 and breast carcinoma.